Cholangiocarcinoma research hub

Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma

This study is looking at a drug called ivosidenib for people with a type of bile duct cancer (cholangiocarcinoma) that has a specific gene change (IDH1 mutation). It aims to see if taking ivosidenib after standard chemotherapy and surgery can stop the cancer from coming back.